Martin Treder

Company: LTZ Therapeutics

Job title: CSO

Bio:

Dr. Martin Treder is a seasoned biopharmaceutical leader with two decades of experience in oncology-focused drug discovery and early development. As CSO at LTZ Therapeutics, he guides the development of the company’s pioneering Myeloid Engager Platform, aimed at activating macrophages and monocytes to drive anti-tumor immunity.

Seminars:

Fireside Chat: Emerging Single-Target Pathways & Immune Checkpoints in Myeloid Therapy 9:30 am

Discover novel, single-agent targets beyond CD47 and TREM2 that are showing promise in myeloid-directed therapy Examine the functional diversity of myeloid checkpoints and their role in immune suppression and resistance Evaluate preclinical and translational evidence supporting these emerging targets for monotherapy or future combination strategiesRead more

day: Conference Day One

Fireside Chat: Aligning Regulatory & Funding Strategies to Accelerate Myeloid Drug Translation 4:15 pm

What endpoints, comparators, and biomarkers regulators are prioritizing after a wave of failures in CD47, ILT, and TREM2-based programs How to structure early-phase trials and IND packages to manage risk, especially for novel myeloid reprogramming or depletion strategies What funders (VCs, pharma partners, government) need to see in terms of differentiation, scalability, and patient stratification…Read more

day: Conference Day One